Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-146-5 | CAS number: 7440-36-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://poisoncentres.echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Value used for CSA:
Bioaccumulation potential: no bioaccumulation potential
Absorption rate - oral (%): 0.05-0.3
Absorption rate - dermal (%): 0.1
Absorption rate - inhalation (%): <<1%
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 0.3
- Absorption rate - dermal (%):
- 0.1
Additional information
Overview and quality of the database:
The majority of published data on toxicokinetics of antimony substances summarised in this dossier were generated several decades before the establishment of standardised test guidelines, and thus obviously do not correspond to current requirements. However, they nevertheless represent supportive data, from which the following conclusions can be drawn:
- for highly water-soluble antimony substances such as tartar emetic (potassium antimony tartrate), exact figures for oral absorption are difficult to derive. This is related to several experimental shortcomings, such as lack of a mass balance, inadequate description of dose and test item, and mostly indirect conclusions based on urinary excretion, for example. Therefore, these data at best allow rough estimates of absorbed/excreted amounts as supportive data. Nevertheless, the available published data support the assumption that absorption via the oral route is in the range of 1-5% of the dose for highly water soluble antimony substances.
- calculations based on a comparison of daily dietary intake of Sb, and the total Sb body burdens of stable Sb isotopes in humans (such as Caughtrey et al. 1983) suggest an oral absorption of up to 1% for Sb compounds, regardless of their origin and speciation; however, since Sb(V) is the predominant stable valence state under ambient environmental conditions and therefore the most predominant species in drinking water and diet, this calculation is likely to be biased on the grounds that Sb(V) is likely to be more bioavailable than Sb(III) species.
- for poorly water-soluble substances such as diantimony trioxide (approx. 5-6 orders of magnitude lower in water solubility than antimony trichloride, for example), published data are not available; for this reason, reference is made to a relative bioavailability study specifically with diantimony trioxide in rats (de Bie et al., 2005), which was conducted under GLP and in full OECD guideline compliance. This study is also of highest relevance to any rat study, since it covers the entire dose range (100-1,000 mg/kb bw) for any animal oral studies likely to be conducted, yielding oral absorption rates of 0.3% (at 100 mg/kg bw) and 0.05% (at 1,000 mg/kg bw), respectively.
Oral absorption:
Published data on oral absorption largely pertain to potassium antimony tartrate (also known as tartar emetic) and/to antimony trichloride. Both substances are highly water soluble, and in particular complexes of antimony with tartaric or citric acid are known to be stable and highly soluble, and thus have been used in the past in attempts to enhance the solubility/bioavailability of antimony, for example in pharmaceutical preparations:
species / test system |
dose / test substance |
oral absorption |
comments |
reliability score |
references |
mice/ rats/ monkeys oral (gavage) and i.v dosing |
8-32 mg/kg bw 124Sb Tartar emetic(1) |
oral absorption mice (single dosing 4.6-7.9%, rep. dosing 5%. (assessment for rats/monkeys incomplete) |
Oral absorption assessment based on cumulative urinary excretion; Mass balance 80% (mice)
|
RL=2 |
Waitz et al. (1965) |
rat |
Sb Tartar emetic(1) |
absorption~ 5% |
(2) |
RL=3 |
Moskalev (1964), |
mouse |
not specified |
Absorption max. 1-2% |
Sec. lit (2) No further data available |
|
Walker (1970), sec. citation from Thomas et al. (1973) |
hamster |
2 µCi 124Sb tartrate |
Absorption < 1% |
Exact dose not given, but very low since carrier-free tracer used |
RL=2 |
Felicetti et al. (1974) |
human |
124Sb tartrate |
Absorption ~ 1% ICRP states “much less than 10%) |
Sec. lit (2) No further data available |
|
Rose & Jacobs (1969) |
human (f) |
dose unknown/ Sb sulphide |
Absorption < 5% |
attempted suicide with unknown amount of Sb2S3 |
RL=2 |
Bailly et al. (1991): |
rats |
dose unknown |
Whole body retention: ~ 1% for adults and 25d weanlings |
Exact dose not given, but very low since carrier-free tracer used |
RL=4 |
Inaba et al. (1984) |
mouse |
18.5 MBq/kg |
1.7% calculated for suckling mice |
Exact dose not given, but very low since carrier-free tracer was used |
RL=4 |
Gerber et al. (1982) |
dog |
Nuclear debris |
> 4% |
dose not given |
RL=4 |
Chertok & Lake (1970) |
(1): tartar emetic: potassium antimony tartrate; (2): cited from secondary literature (review)
Furthermore there is one study in which the oral absorption of soluble pentavalent antimony compounds is assessed to be less than 1% (Felicetti, 1974), based upon which ICRP (1981) concluded 1% oral absorption for all pentavalent antimony compounds.
Tissue distribution and elimination:
From published data on soluble antimony substances, it is known that any antimony becomes systemically available in blood with some impact of valence state upon blood partitioning. Antimony (III) is strongly associated with erythrocytes while antimony (V) preferentially partitions to plasma In the few available published studies addressing the aspect of tissue distribution, the highest levels were reported in thyroid, livers, kidney and spleen – other organs are in most cases not comprehensively studied. One very old study (Cowie, 1945) reports levels of 13 and 19 ug/g tissue wet weight for thyroid and liver, respectively, but the analytical procedure casts some doubt on the precision of these values.
The key study for the assessment of tissue distribution and elimination characteristics is a fully guideline-compliant study by de Bie et al. (2005). In this study, 72 hours after a single oral dose of 1,000 mg/kg bw/d to male and female rats, ca. 0.008% of the dose were excreted via urine, with the balance (98.7-100%) representing material excreted via faeces; total tissue levels and residual carcass levels were 0.0003-0.0004% and 0.0017-0.0023%, respectively. The valence state of antimony will impact excretion routes – Sb (III) excretion is primarily fecal whereas urinary excretion is the dominant route of excretion for Sb (V) ions. The detailed tissue analysis yielded (among other tissues with general lower levels, in ng/g of tissue): bone marrow 1192-1996, thyroid 1507-2103, spleen 197-113, livers 41-64 and lungs 41-61 (male-female, respectively). With respect to organs of reproductive function, the following data can be summarised: testes 2.8 ng/g, prostrate 8.5 ng/g; uterus, 11.4 ng/g, ovaries 262 ng/g. In consideration of the very low total amount of antimony (0.0003-0.0004%) in organs altogether, the above values allow the reasonable assumption that organs of male and female reproduction do not represent target organs for antimony trioxide. The collective data indicate that antimony ions are not metabolized within the body but that changes in valence can occur – a slow conversion from Sb(V) to Sb (III) has been documented.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)